For long, brain development and maturation has been thought to be a one-way process, in which plasticity diminishes with age. The possibility that the adult brain can revert to a younger state and regain plasticity has not been considered, often.
In a paper appearing on November 4 in the online open-access journal Molecular Brain, Dr. Tsuyoshi Miyakawa and his colleagues from Fujita Health University show that chronic administration of one of the most widely used antidepressants fluoxetine (FLX, which is also known by trade names like Prozac, Sarafem, and Fontex and is a selective serotonin reuptake inhibitor) can induce a juvenile-like state in specific types of neurons in the prefrontal cortex of adult mice.
In their study, FLX-treated adult mice showed reduced expression of parvalbumin and perineuronal nets, which are molecular markers for maturation and are expressed in a certain group of mature neurons in adults, and increased expression of an immature marker, which typically appears in developing juvenile brains, in the prefrontal cortex. These findings suggest the possibility that certain types of adult neurons in the prefrontal cortex can partially regain a youth-like state; the authors termed this as induced-youth or iYouth.
Network dysfunction in the prefrontal cortex and limbic system, including the hippocampus and amygdala, is known to be involved in the pathophysiology of depressive disorders. Reversion to a youth-like state may mediate some of the therapeutic effects of FLX by restoring neural plasticity in these regions. On the other hand, some non-preferable aspects of FLX-induced pseudo-youth may play a role in certain behavioral effects associated with FLX treatment, such as aggression, violence, and psychosis, which have recently received attention as adverse effects of FLX.
Interestingly, expression of the same molecular markers of maturation, as discussed in this study, has been reported to be decreased in the prefrontal cortex of postmortem brains of patients with schizophrenia. This raises the possibility that some of FLX's adverse effects may be attributable to iYouth in the same type of neurons in this region. Currently, basic knowledge on this is lacking, and there are several unanswered questions like: What are the molecular and cellular mechanisms underlying iYouth? What are the differences between actual youth and iYouth? Is iYouth good or bad? Future studies to answer these questions could potentially revolutionize the prevention and/or treatment of various neuropsychiatric disorders and aid in improving the quality of life for an aging population.